- Home
- CISS vs BJDX Comparison
CISS vs BJDX Comparison
Compare CISS & BJDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CISS
- BJDX
- Stock Information
- Founded
- CISS 2022
- BJDX 2015
- Country
- CISS Greece
- BJDX United States
- Employees
- CISS N/A
- BJDX N/A
- Industry
- CISS Marine Transportation
- BJDX Medical Specialities
- Sector
- CISS Consumer Discretionary
- BJDX Health Care
- Exchange
- CISS Nasdaq
- BJDX Nasdaq
- Market Cap
- CISS 2.8M
- BJDX 2.9M
- IPO Year
- CISS N/A
- BJDX 2021
- Fundamental
- Price
- CISS $3.30
- BJDX $1.58
- Analyst Decision
- CISS
- BJDX
- Analyst Count
- CISS 0
- BJDX 0
- Target Price
- CISS N/A
- BJDX N/A
- AVG Volume (30 Days)
- CISS 121.3K
- BJDX 2.1M
- Earning Date
- CISS 08-21-2025
- BJDX 08-13-2025
- Dividend Yield
- CISS N/A
- BJDX N/A
- EPS Growth
- CISS N/A
- BJDX N/A
- EPS
- CISS N/A
- BJDX N/A
- Revenue
- CISS $38,174,754.00
- BJDX N/A
- Revenue This Year
- CISS N/A
- BJDX N/A
- Revenue Next Year
- CISS N/A
- BJDX $55.56
- P/E Ratio
- CISS N/A
- BJDX N/A
- Revenue Growth
- CISS N/A
- BJDX N/A
- 52 Week Low
- CISS $2.85
- BJDX $1.46
- 52 Week High
- CISS $23.25
- BJDX $44.50
- Technical
- Relative Strength Index (RSI)
- CISS 41.14
- BJDX 42.16
- Support Level
- CISS $3.20
- BJDX $1.49
- Resistance Level
- CISS $4.00
- BJDX $1.63
- Average True Range (ATR)
- CISS 0.37
- BJDX 0.16
- MACD
- CISS -0.03
- BJDX -0.00
- Stochastic Oscillator
- CISS 8.33
- BJDX 7.29
About CISS C3is Inc.
C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including major national and private industrial users, commodity producers and traders. The company owns and operates a fleet of two dry bulk carriers that transport major bulks such as iron ore, coal and grains, and minor bulks such as bauxite, phosphate and fertilizers. The total cargo-carrying capacity of our fleet is approximately 64,000 dwt.
About BJDX Bluejay Diagnostics Inc.
Bluejay Diagnostics Inc is a medical diagnostics company. It is developing rapid tests using whole blood using its Symphony technology platform to improve patient outcomes in critical care settings. The company's first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings and is a clinically established inflammatory biomarker for the assessment of the severity of infection and inflammation across many disease indications, including sepsis.